On October 16, 2026 Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) at the European Society For Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, which will be held October 23-27, 2026 in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstracts will be available on the ESMO (Free ESMO Whitepaper) website on Monday, October 19, 2026,12:05 am CEST. The data cutoff in the abstract is as of April 3, 2026. The poster presentation will include updated data.
Abstract accepted for poster presentation
Title: A Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic PDAC and NSCLC
Abstract #: 3149P
Presenter: Alexander I. Spira, MD, PhD, FACP (NEXT Oncology, Fairfax, United States of America)
Date, Time: Sunday, October 25, 2026, 12:00 – 12:45 pm CEST
PDAC Investor Webcast and Conference Call Information
The Company will host a PDAC focused investor webcast to discuss these data at 7:30 am ET on Friday, October 23, 2026. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company’s website at www.tangotx.com. The webcast will be available for replay for at least 30 days on the Company website. Analysts who wish to join the teleconference and participate in Q&A should register here.
(Press release, Tango Therapeutics, OCT 16, 2026, View Source [SID1234673534])